Table 2.
The number of DEGs, enriched KEGG pathways, and enriched GO terms
| na | DEGb | KEGGc | GOd | GSEAe | |||||
|---|---|---|---|---|---|---|---|---|---|
| Up | Down | BP | MF | CC | Up | Down | |||
| Gonads | |||||||||
| L2:L1 | 5:6 | 3 | 3 | 0 | 0 | 0 | 0 | 7 | 2 |
| L3:L1 | 6:6 | 60 | 37 | 0 | 0 | 0 | 0 | 2 | 7 |
| Liver | |||||||||
| L2:L1 | 6:6 | 72 | 57 | 2 | 10 | 8 | 0 | 0 | 4 |
| L2:L1 | 6:6 | 153 | 146 | 8 | 36 | 16 | 6 | 0 | 15 |
| G&L | |||||||||
| L2:L1 | 12:12 | 75 | 30 | 0 | 3 | 0 | 0 | 5 | 4 |
| L3:L1 | 11:12 | 196 | 150 | 3 | 10 | 0 | 0 | 2 | 22 |
aNumber of samples represented as (# treatment group):(# control group). bNumber of DEGs defined by adjusted p-values < 0.1 and LFC > 0. cNumber of enriched KEGG pathways identified by ORA with adjusted p-values < 0.05 and the minimum gene count of 5. dNumber of enriched GO terms by ORA with adjusted p-values < 0.05 and the minimum gene count of 5. BP biological process, MF molecular function, and CC cellular component. eNumber of enriched KEGG pathways identified by GSEA with adjusted p-values < 0.05, minimum gene counts: 5 and abs(NES) > 2. Up & Down: the number of pathways enriched by up- and down-regulated genes, respectively